Aptevo Therapeutics (APVO) Interest Expenses (2015 - 2026)
Aptevo Therapeutics (APVO) posted Interest Expenses of $344000.0 for Q1 2026, down 29.22% sequentially from $486000.0 in Q4 2025, and little changed YoY from $344000.0 in Q1 2025.
Aptevo Therapeutics (APVO) Interest Expenses (2015 - 2026) Analysis & Trends
Aptevo Therapeutics has reported Interest Expenses for 12 years, with the latest figure at $344000.0 in Q1 2026.
- Quarterly Interest Expenses changed 0.0% year-over-year to $344000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $344000.0 (changed 0.0% YoY) and the FY2025 annual result came in at $6.0 million, down 18.75% from the prior year.
- Interest Expenses slipped to $344000.0 in Q1 2026 per APVO's latest filing, from $486000.0 in the prior quarter.
- Over five years, Interest Expenses peaked at $1.4 million in Q4 2024 and troughed at $115000.0 in Q1 2023.
- A 5-year average of $670705.9 and a median of $688000.0 in 2024 frame the typical range for Interest Expenses.
- The sharpest annual moves came in 2022 and 2024: Interest Expenses plunged 92.56% in 2022, then soared 199.13% in 2024.
- Over 5 years, Interest Expenses stood at $895000.0 in 2022, then grew by 28.16% to $1.1 million in 2023, then climbed by 19.97% to $1.4 million in 2024, then plunged by 64.68% to $486000.0 in 2025, then declined by 29.22% to $344000.0 in 2026.
- According to Business Quant data, Interest Expenses over the past three periods registered $344000.0, $486000.0, and $1.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 39.74 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 82.05 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -4.89 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 20.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 93.62 Mn |
| 10 | Aptevo Therapeutics | 3.18 Mn | -6.61 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 688,000.00 |
| Jun 30, 2026 | 688,000.00 |
| Mar 31, 2026 | 344,000.00 |
| Mar 31, 2026 | 344,000.00 |
| Dec 31, 2025 | 486,000.00 |
| Dec 31, 2025 | 486,000.00 |
| Sep 30, 2025 | 1.03 Mn |
| Sep 30, 2025 | 1.03 Mn |
| Jun 30, 2025 | 688,000.00 |
| Jun 30, 2025 | 688,000.00 |
| Mar 31, 2025 | 344,000.00 |
| Mar 31, 2025 | 344,000.00 |
| Dec 31, 2024 | 1.38 Mn |
| Dec 31, 2024 | 1.38 Mn |
| Sep 30, 2024 | 1.03 Mn |
| Sep 30, 2024 | 1.03 Mn |
| Jun 30, 2024 | 688,000.00 |
| Jun 30, 2024 | 688,000.00 |
| Mar 31, 2024 | 344,000.00 |
| Mar 31, 2024 | 344,000.00 |